Application of beta-1, 4-galactosyltransferase-IsiRNA in drugs for overcoming liver cancer chemotherapy drug resistance

Abstract

The invention discloses an application of beta1, 4-galactosyl transferase-I siRNA in a drug for overcoming liver cancer chemotherapy resistance, which comprises the following steps: treating liver cancer cells Huh7 and HepG2 with adriamycin, and detecting beta1, 4galactosyl transferase I glycosylation and gene expression level change through PCR (polymerase chain reaction); observing by an inverted microscope to find that adriamycin induces the morphological change of liver cancer cells; detecting the expression of the beta1, 4galactosyltransferase I and MDRI: constructing and transfecting thespecific siRNA of the beta1, 4galactosyltransferase I; observing the influence of the beta1, 4galactosyl transferase I on EMT related molecules; performing scratch experiments to detect the influenceof beta1, 4-galactosyltransferase-I on liver cancer cell migration capacity: adriamycin-induced liver cancer cells huh7, hepG2, observing cell migration capacity, and observing the influence of beta1, 4galactosyltransferase I on liver cancer cell invasion capacity.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of a beta-1,4-galactosyltransferase-IsiRNA in overcoming liver cancer chemotherapeutic drug resistance. Background technique [0002] Primary liver cancer is one of the most common life-threatening diseases in the world. It is the fifth most common and the third deadliest malignant tumor in the world, with an increase of more than 560,000 new cases and more than 500,000 deaths per year. . Current treatment options for liver cancer include surgical resection, liver transplantation, radiofrequency ablation, hepatic arterial chemoembolization, and sorafenib. Although surgery is the first choice for the treatment of liver cancer, most of the patients with liver cancer are found in the middle and late stages, and at this time the tumor can no longer be surgically removed and is forced to take palliative care. It should be noted that although chemotherapy is wide...

AI Technical Summary

Problems solved by technology

In 2009, Black and other scholars interfered with the expression of E-cadherin at the cellular level, and the sensitivity of cells to cetuximab was significantly reduced.

However, the molecular mechanism of the inherent drug resistance of tumors, especially liver cancer, which is generally resistant to chemotherapy, is still unclear.

Images